Literature DB >> 17870033

Mortality in established rheumatoid arthritis.

Sophia M Naz1, Deborah P M Symmons.   

Abstract

Rheumatoid arthritis (RA) is associated with reduced life expectancy. Whether the development of RA initiates this process of premature ageing or is part of it is not clear. The excess mortality is apparent within the first few years of disease and increases with RA disease duration. Most of the excess deaths are attributable to infection, cardiovascular disease (in particular coronary heart disease) and respiratory disease. Deaths due to lung cancer and non-Hodgkin's lymphoma, but not other cancers, are also increased. There is some evidence that effective disease-modifying therapy can improve survival but, overall, survival in RA patients has not improved to the same degree as in the general population over recent decades.

Entities:  

Mesh:

Year:  2007        PMID: 17870033     DOI: 10.1016/j.berh.2007.05.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  57 in total

1.  Cardiovascular risk in patients with rheumatoid arthritis: assessment of several traditional risk parameters and a German risk score model.

Authors:  Janina Willers; Andreas Hahn
Journal:  Rheumatol Int       Date:  2011-11-16       Impact factor: 2.631

2.  Anti-citrullinated heat shock protein 90 antibodies identified in bronchoalveolar lavage fluid are a marker of lung-specific immune responses.

Authors:  Lisa Harlow; Bernadette R Gochuico; Ivan O Rosas; Tracy J Doyle; Juan C Osorio; Timothy S Travers; Carlos C Camacho; Chester V Oddis; Dana P Ascherman
Journal:  Clin Immunol       Date:  2014-08-19       Impact factor: 3.969

3.  Association of Light-Intensity Physical Activity With Lower Cardiovascular Disease Risk Burden in Rheumatoid Arthritis.

Authors:  Samannaaz S Khoja; Gustavo J Almeida; Mary Chester Wasko; Lauren Terhorst; Sara R Piva
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-04       Impact factor: 4.794

Review 4.  Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Iñigo Bermejo; Shijie Ren; Emma Simpson; Mark Clowes; David L Scott; Adam Young; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

5.  Wear testing of a DJOA finger prosthesis in vitro.

Authors:  Thomas J Joyce
Journal:  J Mater Sci Mater Med       Date:  2010-02-11       Impact factor: 3.896

6.  Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap.

Authors:  Diane Lacaille; J Antonio Avina-Zubieta; Eric C Sayre; Michal Abrahamowicz
Journal:  Ann Rheum Dis       Date:  2016-12-28       Impact factor: 19.103

Review 7.  Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Lesley Uttley; Iñigo Bermejo; Shijie Ren; Marrissa Martyn-St James; Ruth Wong; David L Scott; Adam Young; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

8.  Extensive Citrullination Promotes Immunogenicity of HSP90 through Protein Unfolding and Exposure of Cryptic Epitopes.

Authors:  Timothy S Travers; Lisa Harlow; Ivan O Rosas; Bernadette R Gochuico; Ted R Mikuls; Sanjoy K Bhattacharya; Carlos J Camacho; Dana P Ascherman
Journal:  J Immunol       Date:  2016-07-22       Impact factor: 5.422

Review 9.  Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts.

Authors:  Yoel Brito; Marilyn K Glassberg; Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2017-11-09       Impact factor: 4.592

10.  Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Ann-Charlotte Elkan; Niclas Håkansson; Johan Frostegård; Tommy Cederholm; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.